ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Gain The ePRO Advantage With Real-Time Data Collection

  Discover how ePRO automatically incorporates eCOA data into a study, improving the depth, timeliness, and accuracy of patient-reported outcomes data in the following ways.

• Mid-Study Randomization: Ensuring Data Integrity In Oncology Trials

  Miscommunication between supply chain vendors risks costly delays. Discover how unifying physical and digital operations catches issues before they disrupt a trial.

• AI‑Readiness Checklist: Is Your Clinical Data Environment Ready?

  AI impact depends on solid data practices, good governance, and team alignment. This piece highlights what to assess and how organizations can build readiness for future initiatives.

• Why eSource Ensures Data Integrity In Medical Device Clinical Trials

  Learn how eSource data capture offers a more efficient and cost-effective approach to maintaining data integrity.

• Exploring The Potential Of Non-Consumer Smartphones In Clinical Trials

  We selected and evaluated a non-consumer device, to explore its potential as a reliable tool for home-based ePRO measure administration. Here’s what we learned from this usability testing. 

• Where PRO Strategy Goes Wrong

  PRO and COA strategy is now central to trial success. Organizations that capture meaningful patient experience data will gain stronger evidence and a regulatory advantage.

• Paper vs. eCOA: Hard Calculations For Easy Decisions

  Sticker prices often guide purchases, but there's a broader perspective that encompasses total cost. Use this calculator to compare prices of paper COAs or eCOAs, including ePROs, eDiaries, and eClinROs.

• Why eConsent Makes Such A Difference In Patient Adherence And Engagement

  Explore how consent is a critical step that can greatly influence patient enrollment, adherence and retention in the trial.

• Simplifying The Regulatory Submission Process With A Modern CTMS

  Working in collaboration with industry representatives, explore the value that pulling the regulatory submission process into a modern Clinical Trial Management System (CTMS) could have.

• Data Distortions: When Statistics Can Lead Us Astray In Drug Safety

  Post-marketing signals and AE frequency comparisons need careful interpretation. Discover how confounding factors and misunderstood statistics often mislead drug safety professionals.